List of Androgel drug patents

Androgel is owned by Abbvie.

Androgel contains Testosterone.

Androgel has a total of 8 drug patents out of which 0 drug patents have expired.

Androgel was authorised for market use on 29 April, 2011.

Androgel is available in gel;transdermal, gel, metered;transdermal dosage forms.

Androgel can be used as testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

The generics of Androgel are possible to be released after 12 October, 2026.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8466137 ABBVIE Testosterone gel and method of use
Oct, 2026

(3 years from now)

US8466138 ABBVIE Testosterone gel and method of use
Oct, 2026

(3 years from now)

US8741881 ABBVIE Testosterone gel and method of use
Oct, 2026

(3 years from now)

US8729057 ABBVIE Testosterone gel and method of use
Oct, 2026

(3 years from now)

US8754070 ABBVIE Testosterone gel and method of use
Oct, 2026

(3 years from now)

US8466136 ABBVIE Testosterone gel and method of use
Oct, 2026

(3 years from now)

US8759329 ABBVIE Testosterone gel and method of use
Oct, 2026

(3 years from now)

US8486925 ABBVIE Testosterone gel and method of use
Oct, 2026

(3 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 29 April, 2011

Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone

Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in